

Edgar Filing: Inogen Inc - Form 8-K/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Edgar Filing: Inogen Inc - Form 8-K/A

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

This Amendment No. 1 on Form 8-K/A amends the Current Report on Form 8-K filed by the registrant on September 17, 2018 (the “Original 8-K”), to correct certain typographical errors contained in the “Number of Unvested Shares as of 1/2/2019 (assuming continued employment through such date)” column of Schedule A of the Transition Agreement filed as an exhibit to the Original 8-K. The corrected version of Schedule A is included in the copy of the agreement filed as an exhibit hereto. Other than correcting the typographical errors, all other information included in the Original 8-K is unchanged. Attached as Exhibit 10.1 and incorporated herein by reference is a copy of the Transition Agreement with the typographical errors in Schedule A corrected.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Description

10.1 Transition Agreement and Release by and between the Company and Matthew Scribner, dated September 14, 2018.

EXHIBIT INDEX

Exhibit

No. Description

10.1 Transition Agreement and Release by and between the Company and Matthew Scribner, dated September 14, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INOGEN, INC.

Date: September 18, 2018 By: /s/ Alison Bauerlein
Alison Bauerlein

Executive Vice President, Finance,

Chief Financial Officer, Secretary and Treasurer